In MS and other neurodegenerative diseases, the neuroprotective effects of cannabinoids have been attributed to stimulation of CB1R, the most abundant GPCR in the brain, whereas CB2R, the non-psychotropic cannabinoid receptor, has almost exclusively been associated with immunomodulatory effects. The gene discussed is CNR1; the disease is neurodegenerative disease.